The biotechnology industry in India is undergoing a transformational journey, with innovative startups pushing the boundaries of medical research and technology. One such trailblazer is Bhubaneswar-based biotech startup Exsure, co-founded in 2021 by Swastika Paul and Abhishek Dutta. With its recent Rs 3 crore seed funding led by Unicorn India Ventures, Exsure is poised to redefine cancer treatment with its pioneering exosome-based drug delivery platform.

Lets explore Exsure’s remarkable journey, its breakthrough innovations, and its vision for a future where cancer treatments are less toxic and more effective, all while positioning itself as a global leader in biotechnology.

Cancer continues to be one of the most feared diseases worldwide, not just for patients but for their families. While chemotherapy remains a mainstay in cancer treatment, it often comes at a steep cost, 13% of in-treatment cancer patients succumb to the toxic side effects of chemotherapy drugs. Recognizing this critical challenge, Exsure has set out to change the narrative.

At the heart of its mission is a patented exosomal drug delivery platform, which targets both cancer cells and the elusive cancer stem cells responsible for relapses. This approach not only reduces the toxic effects of chemotherapy but also minimizes the chances of cancer returning, significantly improving the quality of life for patients.

In the words of Swastika Paul, Chief Scientific Officer and Co-Founder of Exsure, “Our vision is to empower millions of cancer patients worldwide by making chemotherapy drugs less toxic and more targeted.”

The recent Rs 3 crore seed funding marks a critical milestone in Exsure’s journey. This capital injection will be used to achieve several key objectives:

1.    Advancing Research: Exsure will complete the milestones of its ongoing non-clinical study, leveraging its patented technology to validate the efficacy of its platform.

2.    Global Expansion: The startup aims to scale its reach globally, introducing its in-house R&D products—Exosure, Leucosure, PlantExosure, and Dr. Berries—to new markets.

3.    Team Building: Strengthening its talent pool will be a priority as Exsure prepares for future growth.

4.    Regulatory Approvals: The company plans to present its data for CDSCO (Central Drugs Standard Control Organization) approval, a critical step for bringing its products to market.

The backing from Unicorn India Ventures not only provides financial support but also validates Exsure’s potential to transform cancer therapeutics. Bhaskar Majumdar, Managing Partner at Unicorn India Ventures, highlighted Exsure’s role in advancing therapeutic science, stating, “Exsure’s exosome-based drug delivery platform places it at the forefront of biotechnology innovation, offering hope to countless patients worldwide.”

Exsure’s product portfolio is a testament to its commitment to innovation. The startup has developed a range of R&D-focused tools that cater to various aspects of scientific research:

1.    Exosure: A revolutionary 3-in-1 exosome isolation reagent that simplifies and accelerates exosome research.
2.    Leucosure: A cutting-edge PBMC (Peripheral Blood Mononuclear Cell) isolation reagent that aids in advanced cellular studies.
3.    PlantExosure: India’s first plant exosome isolation reagent, reflecting Exsure’s versatility in addressing diverse research needs.

These products have already gained traction, with the startup reporting a five-fold revenue growth last fiscal year. Exsure is set to serve over 50 clients this year, highlighting its rapid rise in the biotech landscape.

Exsure’s innovation has not gone unnoticed on the global stage. The startup has been selected for the prestigious OIST Innovation Accelerator program in Japan, a platform that will provide critical support for business expansion and clinical trials. This recognition positions Exsure as a rising star in the international biotechnology arena.

Additionally, the company’s vision aligns with the Indian biotechnology industry’s growth trajectory. According to the India Brand Equity Foundation (IBEF), the industry is expected to grow from $150 billion in 2025 to $270–300 billion by 2030, contributing 19% to the global biotech market by 2025. Exsure’s focus on cutting-edge research and global expansion puts it in an ideal position to capitalize on this growth.

Exsure’s journey is rooted in the personal experiences of its founders. During their PhD research, Swastika Paul and Abhishek Dutta witnessed the devastating impact of chemotherapy toxicity on patients. Driven by a shared vision to make a difference, they embarked on a mission to develop solutions that would reduce the collateral damage of cancer treatments.

Their efforts have already yielded significant results. In collaboration with a CRO (Contract Research Organization), Exsure has initiated non-clinical studies in India and achieved critical milestones in preclinical research. These achievements reflect the startup’s relentless pursuit of excellence.

While Exsure’s progress has been commendable, the road ahead is not without challenges. Developing cutting-edge biotechnology solutions requires substantial funding, rigorous testing, and regulatory approvals. However, Exsure’s strategic roadmap and the support of investors like Unicorn India Ventures provide a strong foundation for overcoming these hurdles.

In the coming 12 months, Exsure plans to:

Complete its non-clinical study.
Expand its marketing and sales efforts globally.
Strengthen its team to support future growth.

These initiatives will not only accelerate Exsure’s growth but also contribute to India’s standing as a global biotech hub.

At its core, Exsure’s mission is about transforming lives. By reducing the toxic side effects of chemotherapy and improving the efficacy of cancer treatments, the startup is offering a lifeline to patients battling one of the most challenging diseases of our time.

As Exsure continues to innovate and expand, it is poised to make a profound impact on the biotechnology industry and, more importantly, on the lives of millions of cancer patients around the world.

This journey is a testament to the power of innovation and determination. From its humble beginnings in Bhubaneswar to its recognition on the global stage, the startup embodies the spirit of India’s biotechnology revolution. With its exosome-based drug delivery platform, groundbreaking products, and visionary leadership, Exsure is not just addressing the challenges of cancer treatment—it is redefining what’s possible in the fight against cancer.

As the Indian biotechnology industry continues to grow, Exsure stands out as a ray of hope and progress. Its journey reminds us that with the right blend of passion, innovation, and support, even the most daunting challenges can be overcome